[go: up one dir, main page]

BR9909730A - Dihidropirimidinas - Google Patents

Dihidropirimidinas

Info

Publication number
BR9909730A
BR9909730A BR9909730-3A BR9909730A BR9909730A BR 9909730 A BR9909730 A BR 9909730A BR 9909730 A BR9909730 A BR 9909730A BR 9909730 A BR9909730 A BR 9909730A
Authority
BR
Brazil
Prior art keywords
dihydropyrimidines
compounds
relates
formula
dihidropirimidinas
Prior art date
Application number
BR9909730-3A
Other languages
English (en)
Other versions
BR9909730B1 (pt
Inventor
Juergen Stoltefuss
Siegfried Goldmann
Thomas Kraemer
Karl-Heinz Schlemmer
Ulrich Niewoehner
Arnold Paessens
Erwin Graef
Stefan Lottmann
Karl Deres
Olaf Weber
Joern Stoelting
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9909730A publication Critical patent/BR9909730A/pt
Publication of BR9909730B1 publication Critical patent/BR9909730B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"DIHIDROPIRIMIDINAS"<D>. A invenção refere-se a compostos da fórmula gerais (I) ou (Ia) Além disso, a invenção refere-se a processos para a preparação dos compostos da fórmula (I) ou (Ia) e a sua aplicação como medicamentos, especialmente para o tratamento e a profilaxia da hepatite B.
BRPI9909730-3A 1998-04-18 1999-04-07 dihidropirimidinas, bem como processo para a preparação e aplicação das mesmas. BR9909730B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19817264A DE19817264A1 (de) 1998-04-18 1998-04-18 Neue Dihydropyrimidine
PCT/EP1999/002344 WO1999054326A1 (de) 1998-04-18 1999-04-07 Dihydropyrimidine

Publications (2)

Publication Number Publication Date
BR9909730A true BR9909730A (pt) 2000-12-19
BR9909730B1 BR9909730B1 (pt) 2012-09-04

Family

ID=7864972

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9909730-3A BR9909730B1 (pt) 1998-04-18 1999-04-07 dihidropirimidinas, bem como processo para a preparação e aplicação das mesmas.
BRPI9917862A BRPI9917862B8 (pt) 1998-04-18 1999-04-07 dihidropirimidinas, bem como processo para a preparação e aplicação das mesmas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9917862A BRPI9917862B8 (pt) 1998-04-18 1999-04-07 dihidropirimidinas, bem como processo para a preparação e aplicação das mesmas.

Country Status (36)

Country Link
US (3) US6696451B1 (pt)
EP (1) EP1080086B1 (pt)
JP (2) JP4590097B2 (pt)
KR (1) KR100636771B1 (pt)
CN (1) CN1159311C (pt)
AR (1) AR018187A1 (pt)
AT (1) ATE223401T1 (pt)
AU (1) AU740318B2 (pt)
BG (1) BG64649B1 (pt)
BR (2) BR9909730B1 (pt)
CA (1) CA2328780C (pt)
CO (1) CO5021127A1 (pt)
CU (1) CU23049A3 (pt)
CZ (1) CZ293482B6 (pt)
DE (2) DE19817264A1 (pt)
DK (1) DK1080086T3 (pt)
ES (1) ES2183548T3 (pt)
GT (1) GT199900056A (pt)
HU (1) HUP0102372A3 (pt)
ID (1) ID27263A (pt)
IL (2) IL138584A0 (pt)
MY (1) MY126527A (pt)
NO (2) NO321985B1 (pt)
NZ (1) NZ507569A (pt)
PE (1) PE20000427A1 (pt)
PL (1) PL193898B1 (pt)
PT (1) PT1080086E (pt)
RU (1) RU2245881C9 (pt)
SI (1) SI1080086T1 (pt)
SK (1) SK286407B6 (pt)
SV (1) SV1999000047A (pt)
TR (1) TR200003011T2 (pt)
TW (1) TW548274B (pt)
UA (1) UA63998C2 (pt)
WO (1) WO1999054326A1 (pt)
ZA (1) ZA200005136B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4289100A (en) * 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
AU5568400A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
AU3009801A (en) * 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
CN101104617B (zh) 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104604B (zh) 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
RU2452733C2 (ru) * 2007-04-27 2012-06-10 Пэдью Фарма Л.П. Антагонисты trpv1 и их применение
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
RU2493826C2 (ru) 2007-07-12 2013-09-27 Новартис Аг Пероральные фармацевтические растворы, содержащие телбивудин
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2015002511A (es) 2012-08-24 2016-03-08 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
EP2892893B2 (en) 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
AU2013342164A1 (en) * 2012-11-09 2015-06-04 Assembly Biosciences, Inc. Alternative uses for HBV assembly effectors
BR102014028162A2 (pt) * 2013-11-12 2015-09-08 Dow Agrosciences Llc processo para fluoração de compostos
KR20160077050A (ko) 2013-11-19 2016-07-01 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
JP6382977B2 (ja) 2013-11-27 2018-08-29 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. ジヒドロピリミジン誘導体およびその中間体の製造方法
JP2017512789A (ja) 2014-03-28 2017-05-25 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. ジヒドロピリミジン化合物及び医薬におけるその適用
AU2015266481B2 (en) * 2014-05-30 2018-06-07 Qilu Pharmaceuticals Co., Ltd. Dihydropyrimido fused ring derivative as HBV inhibitor
CN105153164B (zh) * 2014-05-30 2018-10-30 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
EP3253751B1 (en) 2015-02-07 2020-12-09 Sunshine Lake Pharma Co., Ltd. Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals
WO2019001420A1 (en) * 2017-06-27 2019-01-03 Janssen Pharmaceutica Nv HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly
KR20200083552A (ko) 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
CN111448199A (zh) 2017-11-02 2020-07-24 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺
CA3097784A1 (en) * 2018-05-08 2019-11-14 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
US20220009945A1 (en) * 2018-11-02 2022-01-13 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
JP2022511819A (ja) 2018-12-20 2022-02-01 ヤンセン ファーマシューティカ エヌ.ベー. ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染症を治療する方法
MX2021013105A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb).
SG11202111236UA (en) 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
US20220227789A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
PH12021552749A1 (en) 2019-04-30 2022-07-11 Aicuris Gmbh & Co Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130304C (pt) * 1964-02-12
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (pt) 1973-01-23 1975-11-14 Ciba Geigy Ag
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3234684A1 (de) 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
JPS60185764A (ja) 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピリジン誘導体の新規な製造法
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
GB8906168D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
BR9713027A (pt) * 1996-11-12 2000-01-25 Novartis Ag Derivados de pirazol úteis como herbicidas
SE9702564D0 (sv) 1997-07-02 1997-07-02 Astra Ab New compounds

Also Published As

Publication number Publication date
CU23049A3 (es) 2005-06-24
BR9909730B1 (pt) 2012-09-04
DE19817264A1 (de) 1999-10-21
SK15652000A3 (sk) 2001-04-09
ATE223401T1 (de) 2002-09-15
AR018187A1 (es) 2001-10-31
TW548274B (en) 2003-08-21
CZ293482B6 (cs) 2004-05-12
ID27263A (id) 2001-03-22
WO1999054326A8 (de) 1999-12-29
US20070117812A1 (en) 2007-05-24
ZA200005136B (en) 2001-03-02
CZ20003871A3 (cs) 2001-01-17
NO321985B1 (no) 2006-07-31
SK286407B6 (sk) 2008-09-05
MY126527A (en) 2006-10-31
NZ507569A (en) 2002-04-26
HUP0102372A3 (en) 2003-01-28
ES2183548T3 (es) 2003-03-16
JP4590097B2 (ja) 2010-12-01
BG104812A (en) 2001-06-29
CA2328780C (en) 2008-09-23
TR200003011T2 (tr) 2001-01-22
SI1080086T1 (en) 2003-02-28
PL193898B1 (pl) 2007-03-30
EP1080086A1 (de) 2001-03-07
US7514565B2 (en) 2009-04-07
NO20045259L (no) 2000-12-13
PL343481A1 (en) 2001-08-27
RU2245881C2 (ru) 2005-02-10
NO20005215L (no) 2000-12-13
KR20010042788A (ko) 2001-05-25
AU3813399A (en) 1999-11-08
BRPI9917862B8 (pt) 2021-05-25
UA63998C2 (uk) 2004-02-16
CN1305471A (zh) 2001-07-25
CN1159311C (zh) 2004-07-28
BG64649B1 (bg) 2005-10-31
JP2002512243A (ja) 2002-04-23
PT1080086E (pt) 2002-12-31
BRPI9917862A2 (pt) 2010-12-07
DE59902573D1 (en) 2002-10-10
CA2328780A1 (en) 1999-10-28
AU740318B2 (en) 2001-11-01
DK1080086T3 (da) 2002-12-23
CO5021127A1 (es) 2001-03-27
BRPI9917862B1 (pt) 2013-05-07
EP1080086B1 (de) 2002-09-04
JP2010241837A (ja) 2010-10-28
US6696451B1 (en) 2004-02-24
PE20000427A1 (es) 2000-06-25
IL138584A0 (en) 2001-10-31
NO20005215D0 (no) 2000-10-17
WO1999054326A1 (de) 1999-10-28
SV1999000047A (es) 2000-06-23
JP5237332B2 (ja) 2013-07-17
KR100636771B1 (ko) 2006-10-23
GT199900056A (es) 2000-10-07
HUP0102372A2 (hu) 2001-12-28
IL138584A (en) 2006-09-05
US20040167135A1 (en) 2004-08-26
HK1039119A1 (en) 2002-04-12
RU2245881C9 (ru) 2006-02-10
NO329020B1 (no) 2010-07-26

Similar Documents

Publication Publication Date Title
BR9909730A (pt) Dihidropirimidinas
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BR0014679A (pt) 2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
BR9800228A (pt) Compostos de peridilfurano e piridiltiofeno
SE0102315D0 (sv) Compounds
CR6540A (es) Trifluorobutenos nematicidas
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
MXPA02011288A (es) Tioacetamidas substituidas.
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
TR200101649T2 (tr) Piperazin türevleri.
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0213037A (pt) Derivados de pirimidina
ATE410139T1 (de) Kosmetische zusammensetzung auf basis von zink- und kupfersulfaten und sucralphat
NO20010940D0 (no) TAN-1057 derivater
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
AU4568400A (en) Sphingomyelinase inhibitor
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I&#39;e göre bileşiklerin kullanımı

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/09/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.